Professor James St John is a Professor in the Institute for Biomedicine and Glycomics at Griffith University, serving as Head of the Clem Jones Centre for Neurobiology and Stem Cell Research. He holds a PhD from the University of Melbourne awarded on 1 January 1996 in agricultural science, focusing on carbohydrate metabolism in pasture grasses, a Bachelor of Letters in International Development from Deakin University in 1995, and a Bachelor's degree in Agricultural Science. St John began his career in agricultural science before transitioning to neuroscience, where he has led the Clem Jones Centre since its inception. His appointment as Head at Griffith University dates back to at least 2016. He supervises PhD students and contributes to teaching in biomedical fields.
St John's research centers on neurobiology and stem cell research, particularly olfactory ensheathing cells for repairing spinal cord injuries and nervous system damage. Key projects include the world-first Spinal Injury Project clinical trial, which commenced in August 2025 using autologous olfactory ensheathing cells to treat chronic spinal cord injuries, supported by a $6.8 million NHMRC grant awarded in 2024. Additional funding supported cell transplantation research in 2023. His team operates the Griffith Smell Clinic, investigating olfactory dysfunction and links to Alzheimer's disease, including studies on bacteria from nose picking. St John received the 2025 NHMRC Consumer Involvement Award and was a runner-up in the Institute for Biomedicine and Glycomics Executive Directors Award. With over 4,564 citations, an h-index of 37, and 2,197 citations since 2021 on Google Scholar, his influence is substantial. Notable publications include 'Three-dimensional printing of biological matters' (2016), 'Survival and Integration of Transplanted Olfactory Ensheathing Cells' (2019), 'The Immunological Roles of Olfactory Ensheathing Cells in the Treatment of Spinal Cord Injury' (2022), and 'Designing a Clinical Trial with Olfactory Ensheathing Cell Transplantation for Spinal Cord Injury Repair' (2022). He serves as Editor-in-Chief of Neuroglia and engages in professional activities advancing translational neuroscience.